U.K. Precision Medicine Market Size & Outlook, 2026-2033
The precision medicine market in the UK is expected to reach a projected revenue of US$ 15,236.5 million by 2033. A compound annual growth rate of 19% is expected of the UK precision medicine market from 2026 to 2033.
The UK precision medicine market generated a revenue of USD 3,824.6 million in 2025 and is expected to reach USD 15,236.5 million by 2033.
The UK market is expected to grow at a CAGR of 19% from 2026 to 2033.
In terms of segment, therapeutics was the largest revenue generating application in 2025.
Diagnostics is the most lucrative application segment registering the fastest growth during the forecast period.
Precision medicine market data book summary
Market revenue in 2025
USD 3,824.6 million
Market revenue in 2033
USD 15,236.5 million
Growth rate
19% (CAGR from 2026 to 2033)
Largest segment
Therapeutics
Fastest growing segment
Diagnostics
Historical data
2021 - 2024
Base year
2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Diagnostics, Therapeutics
Key market players worldwide
Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares
Other key industry trends
In terms of revenue, UK accounted for 3.3% of the global precision medicine market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Europe, Germany precision medicine market is projected to lead the regional market in terms of revenue in 2033.
UK is the fastest growing regional market in Europe and is projected to reach USD 15,236.5 million by 2033.
The presence of sophisticated healthcare infrastructure, collaborations between key market players, and launch of novel products are anticipated to contribute to market growth in the UK. Government support & initiatives are expected to further propel the growth of the country’s precision medicine market in the coming years.
For instance, in 2020, the UK government issued GENOME UK: 2020 national genomic healthcare strategy, which focused on the strategies to improve genomics in healthcare and research. Similarly, in December 2018, Genomics plc, a UK-based company, raised funding of USD 40.3 million (EUR 37 million) for developing personalized medicine.
In January 2022, Eagle Genomics, a UK-based company, raised a funding of USD 20 million, which is aimed toward innovation in personalized medicine. In addition, in February 2024, an innovative AI-driven project, NextGen, was launched in the UK and EU to personalize therapies for cardiovascular disease patients.
U.K. precision medicine diagnostics therapeutics market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Precision Medicine Market Outlook will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 94.13% in 2025.
Horizon Databook has segmented the U.K. precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2021 to 2033.
The presence of sophisticated healthcare infrastructure, collaborations between key market players, and launch of novel products are anticipated to contribute to market growth in the UK. Government support & initiatives are expected to further propel the growth of the country’s precision medicine market in the coming years.
For instance, in 2020, the UK government issued GENOME UK: 2020 national genomic healthcare strategy, which focused on the strategies to improve genomics in healthcare and research. Similarly, in December 2018, Genomics plc, a UK-based company, raised funding of USD 40.3 million (EUR 37 million) for developing personalized medicine.
In January 2022, Eagle Genomics, a UK-based company, raised a funding of USD 20 million, which is aimed toward innovation in personalized medicine. In addition, in February 2024, an innovative AI-driven project, NextGen, was launched in the UK and EU to personalize therapies for cardiovascular disease patients.
U.K. Precision Medicine Market Application Outlook (Revenue, USD Million , 2021-2033)
Diagnostics
Therapeutics
U.K. Precision Medicine Market End Use Outlook (Revenue, USD Million , 2021-2033)
Home Care
Hospitals
Clinical Laboratories
Others
Reasons to subscribe to precision medicine diagnostics therapeutics market databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of precision medicine diagnostics therapeutics market databook
Our clientele includes a mix of precision medicine diagnostics therapeutics market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.K. precision medicine diagnostics therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into U.K. precision medicine diagnostics therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.